The Ruti Aga Case: Six Years Came Not From the Drug but From a Prescription That Never Existed

There is a date in the statement, and there is no year. The Athletics Integrity Unit's ruling, released on Thursday, counts Ethiopian marathoner Ruti Aga's ban from 10 September — the day she was provisionally suspended. The length: six years. Which year, the source does not say, and that is a reporting defect, not an athlete's.

The number that is clearly sourced is the one that stings more than the year. Break six apart: two years for the substance, four for the paper. The substance is methylprednisolone — a glucocorticoid with no demonstrated endurance benefit. The paper is a prescription written by a clinic that did not exist.

The anomaly is not that a runner was banned for six years. It is that a drug with close to zero measured value in a marathon ended a career. The drug did not deliver those six years. The document did.

Bhubaneswar, July 2026. I was charting every throw of the Asian Athletics Championships javelin final — not for a reason, just a habit. I have carried one rule since: what the source does not contain does not enter the report. Much will not enter this report, because the AIU statement gives almost nothing on performance. I trusted the stopwatch until the day it lied to my face — the day a coach's hand-timed 58.9 became a FAT-verified 60.4 on the official sheet. Since then I do not report a mark, I audit it. That habit has now moved from splits to prescriptions.

Context: one title, three runner-up finishes, one March morning

Aga is 32. She won the 2026 Tokyo Marathon and finished second at three World Marathon Majors. My own race log carries her at 2:18:34 in Berlin 2026 and 2:20:40 in Tokyo 2026 — and I should flag clearly that neither figure appears in the AIU statement; they come from my archive and remain independently unverified. What the statement does give: she won a half marathon in China in March this year, and a sample collected there came back positive. No race name, no mark, no field depth, no margin.

That means performance analysis here is impossible. The only performance fact is the win itself — which implies the sort of elite field that attracts in-competition testing, otherwise no AIU sample would exist.

One sentence explains the event landscape: Ethiopia's sub-2:16 cohort has reached world-record level, and a 2:18–2:20 marathoner is not automatically selectable at home. That number matters, because it decides how much this ban costs the sport — and the answer is close to nothing.

The second piece of context, absent from the statement but central to the case economics: China's label-race circuit. Between Majors, it is the easiest income tier for East African elites — large appearance fees, few races, low risk. It is also now the AIU's highest-yield testing zone. Two economies are colliding in the same race, and Aga is the collision's output.

Core: S9 versus S1, and the clinic that was not there

First technical correction, and it is not small. Methylprednisolone is a glucocorticoid, WADA Prohibited List class S9 — not an anabolic steroid (S1). Media reports called it a prohibited steroid and said WADA classes it as performance enhancing. That is incomplete and misleading. S9 substances are prohibited in-competition only, and only by injection, oral or rectal route.

The consequence: the case turns on route and timing relative to competition, not on steroid use. A therapeutic knee injection out of competition is entirely legal; it becomes a violation only if residues are present in competition. A road race's testing window opens at 23:59 the day before the race, which is how an injection given days earlier gets caught. This is exactly where the case becomes technical — and exactly where Aga had a real defence.

Second: the knee explanation is not absurd. Intra-articular methylprednisolone for knee synovitis is standard sports medicine in distance runners, and a load-bearing knee is a known failure mode in marathon training. That plausibility is precisely what makes the forgery decisive. A genuinely documented treatment would have been defended with real records, a TUE process, or a documented washout period. Forged paper becomes necessary only when real paper does not exist.

Third, and heaviest: the forgery chain contains three independent verification failures. The clinic named on the prescription did not exist. The doctor who signed it was a family member with no medical registration. And when he claimed to have used an old prescription pad from a former workplace, that clinic publicly disowned the claim. One verification failure is an accident. Three is a process.

Fourth, easily skipped: the four-year tampering sanction did not come from a document alone. It came from an interview — from statements given under questioning. If the paper had been produced by an outsider, accountability would point outward. When the statements are the athlete's own, the sanction lands on the athlete.

Now the arithmetic. Two plus four, six. This is standard, not exceptional. Two years is the baseline for a specified substance without proven intent; four years is the Code's standard tampering sanction. The addition means the panel rejected the no-significant-fault mitigation that could have pulled the presence violation below two years. The athlete deleted her own strongest defence.

There is a quiet paradox the spreadsheet records without complaint: forged documentation is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction — two years stayed two years. The panel booked the intent to conceal under tampering, not under presence. The spreadsheet never argues back, which is why I trust it more than pundits — and here it says the sentence was assembled from two separate acts, not one story.

The outcome: six years from 10 September. Back at 38. The 2028 Olympic cycle gone entirely. Annulment of the March result and its prize money is near-certain — not stated in the statement, but standard AIU practice, so I file it as an inference. The 2026 Tokyo title does not fall automatically; it falls only if earlier use is established, and the statement contains nothing of the sort.

Contrarian: the risk of reading a paperwork case as a drug case

Read this as another doping bust and you lose the only new thing in it. The steroid label builds a frame in which a career ended for a performance edge — when the drug is a supporting character and the document is the lead.

That difference matters because it sends the deterrent signal to the wrong place. Every young runner in every developing road-racing cluster will take one lesson from this: do not take the drug. The actual lesson is: do not fabricate the paper, because the AIU now reads paper. The first lesson is familiar and has limited reach. The second is new, and it is this case's real information gain.

Nor should six years be read as automatic proof of severity. Two years and four years are both Code baselines. What is unusual is not the length but that a presence violation was established for a substance that does not build endurance. That is a question of class, and it makes the case usable from both directions. One camp will cite AIU rigour. Another will cite disproportionate enforcement against African road runners. Both will work from the same number — six. I would ask both the same question: would six years have arrived without the drug? This article's answer is no. Two would have.

On the competitive landscape, the effect is zero. Aga's slot in Ethiopian selection mathematics is filled by tomorrow morning, because she owns three Major runner-up finishes and zero global championship medals. Loss-to-the-sport framing is sentiment, not measurement. A single number is a rumour; a season of them is a testimony — and hers stands, even as a banned season.

My kill criteria, published before this piece: three readings could falsify it. First, if the reasoned decision shows the injection was in-competition and the intent was to mask chronic injury while protecting appearance-fee income, the performance lens returns and this becomes an edge case. Second, if earlier results are annulled and the Tokyo 2026 title goes, the historical record changes and my bifurcated-legacy line must be retracted. Third, if the investigation reaches an agent or management and establishes fault there, this is not one person's error but a system failure — and my self-inflicted-damage frame is incomplete. The third is not the least likely of the three.

Takeaway

The AIU's enforcement frontier has moved. The old question was whether a substance is in the body. The new question is whether the paper is real. Over the next two years a large share of road-racing cases will come from document verification rather than detection, and any athlete assuming a knee injection and a prepared script will clear the AIU desk before it reaches the lab is counting wrong. I learned to subtract the noise before I learned to add the wins — here the noise is the word steroid, and what remains standing is a clinic that never existed.

One question the statement does not answer, and the next one probably will not either: what happens to the family member who signed as a doctor? What happens to the agent, if there was one? The sanction landed on the athlete and the career was the athlete's. The network is still standing, and next time it will need the same pad.